---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-24-000150"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:45:51.191128+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Immunovant stockholders elect directors, ratify auditor, approve compensation at 2024 annual meeting

## Summary
- Three directors (Salzmann, Migausky, Hughes) elected with over 97M votes for each, ~6.5M broker non-votes.
- Ernst & Young ratified as auditor for FY ending March 31, 2025: 138,241,628 for, 16,740 against.
- Non-binding advisory approval of named executive officer compensation: 128,494,310 for, 3,249,170 against.
- Approximately 95% of eligible shares (138.3M) represented at the meeting.

## SEC filing metadata
- accession: 0001764013-24-000150
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000150/0001764013-24-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000150/imvt-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-24-000150
- JSON: https://secwatch.observer/filing/0001764013-24-000150.json
- Plain text: https://secwatch.observer/filing/0001764013-24-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.